FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317163498> ?p ?o ?g. }

• W2317163498 abstract "Bisphosphonates have proven efficacy in reducing skeletal complications in metastatic breast cancer. Potent third generation bisphosphonates are more effective but the dose limiting toxicity is usually renal. Ibandronate is a 3rd generation bisphosphonate available in oral and intravenous form which offers many clinical advantages in ease of administration and lack of renal toxicity. A dose-response effect has been observed between 2mg and 6 mg IV doses and there is a single study suggesting that higher dosing (4 mg IV daily for 3 days) is tolerable and effective. A steady state of oral ibandronate is achieved at 8 days with oral administration but time to response is not known. In trials so far, IV ibandronate 6mgs appears safe. Due to lack of renal toxicity there is potential for further escalation of IV ibandronate. The objective of this study was to establish if an IV loading dose can improve efficacy and time to biochemical response compared to oral standard therapy and to assess the safety of a higher IV dose of ibandronate. Methods and Patients: This was an open randomised phase II study conducted on patients with bone metastases from breast cancer comparing IV ibandronate 12 mg on day 1 followed by oral ibandronate 50 mgs daily (Arm A) with standard oral therapy of 50 mgs daily from day 1 (Arm B). The primary study end-point was the percentage reduction in serum CTX from baseline by day 5 on study, secondary end- points were the percentage reduction of bone turnover markers including serum CTX from baseline end of week 8 and percentage reduction in urine NTX from baseline to day 5 on study and baseline to end of week 1–8. Bone pain was recorded by Brief Pain Inventory. Patients had metastatic breast cancer with proven bone metastases, no previous treatment with bisphosphonates or other bone directed therapy within 6 months and no change in systemic therapy within a 3 months preceding trial therapy. Sample size of 22 patients in each arm was calculated to give a 90% chance detecting a 20% difference in average percentage reduction between the IV and oral arms. Results: Seventeen patients were randomised to each study arm. A more rapid change in bone turnover markers was demonstrated in patients recieving the 12 mg loading dose of ibandronate. There was a 15.8% greater reduction of serum CTX in Arm A compared with Arm B at day 5, p=0.005. The percentage reduction of serum PINP at day 5 was also greater in Arm A, p=0.002. Over the 8 week period of study there was no overall significant difference in bone turnover markers. All patients had pain at study entry, median baseline pain severity scores were 3 in study arm and 4 in controls. Average bone pair score remained higher in treatment arm B at the end of 8 weeks. There were no additional adverse side-effects following administration of 12 mg of IV ibandronate and no evidence of additional renal toxicity. Conclusion: A 12 mg dose of IV ibandronate can be safely administered without additional renal toxicity. A rapid reduction in bone turnover markers is demonstrated within 5 days of IV loading dose of ibandronate. Potential exists for dose escalation of ibandronate. The clinical benefit of a more rapid reduction in bone turnover markers is unknown. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-16-05." @default.
• W2317163498 created "2016-06-24" @default.
• W2317163498 creator A5055713039 @default.
• W2317163498 creator A5075442632 @default.
• W2317163498 creator A5090741659 @default.
• W2317163498 date "2011-12-15" @default.
• W2317163498 modified "2023-09-27" @default.
• W2317163498 title "P4-16-05: A Randomized Phase 2 Study of a Loading Dose of Ibandronate in Patients with Bone Metastases from Breast Cancer." @default.
• W2317163498 doi "https://doi.org/10.1158/0008-5472.sabcs11-p4-16-05" @default.
• W2317163498 hasPublicationYear "2011" @default.
• W2317163498 type Work @default.
• W2317163498 sameAs 2317163498 @default.
• W2317163498 citedByCount "0" @default.
• W2317163498 crossrefType "proceedings-article" @default.
• W2317163498 hasAuthorship W2317163498A5055713039 @default.
• W2317163498 hasAuthorship W2317163498A5075442632 @default.
• W2317163498 hasAuthorship W2317163498A5090741659 @default.
• W2317163498 hasConcept C121608353 @default.
• W2317163498 hasConcept C126322002 @default.
• W2317163498 hasConcept C126894567 @default.
• W2317163498 hasConcept C141071460 @default.
• W2317163498 hasConcept C143998085 @default.
• W2317163498 hasConcept C168563851 @default.
• W2317163498 hasConcept C170033053 @default.
• W2317163498 hasConcept C203092338 @default.
• W2317163498 hasConcept C2775930923 @default.
• W2317163498 hasConcept C2776541429 @default.
• W2317163498 hasConcept C2777251235 @default.
• W2317163498 hasConcept C2777288759 @default.
• W2317163498 hasConcept C2777556957 @default.
• W2317163498 hasConcept C2777783956 @default.
• W2317163498 hasConcept C29730261 @default.
• W2317163498 hasConcept C31760486 @default.
• W2317163498 hasConcept C530470458 @default.
• W2317163498 hasConcept C71924100 @default.
• W2317163498 hasConceptScore W2317163498C121608353 @default.
• W2317163498 hasConceptScore W2317163498C126322002 @default.
• W2317163498 hasConceptScore W2317163498C126894567 @default.
• W2317163498 hasConceptScore W2317163498C141071460 @default.
• W2317163498 hasConceptScore W2317163498C143998085 @default.
• W2317163498 hasConceptScore W2317163498C168563851 @default.
• W2317163498 hasConceptScore W2317163498C170033053 @default.
• W2317163498 hasConceptScore W2317163498C203092338 @default.
• W2317163498 hasConceptScore W2317163498C2775930923 @default.
• W2317163498 hasConceptScore W2317163498C2776541429 @default.
• W2317163498 hasConceptScore W2317163498C2777251235 @default.
• W2317163498 hasConceptScore W2317163498C2777288759 @default.
• W2317163498 hasConceptScore W2317163498C2777556957 @default.
• W2317163498 hasConceptScore W2317163498C2777783956 @default.
• W2317163498 hasConceptScore W2317163498C29730261 @default.
• W2317163498 hasConceptScore W2317163498C31760486 @default.
• W2317163498 hasConceptScore W2317163498C530470458 @default.
• W2317163498 hasConceptScore W2317163498C71924100 @default.
• W2317163498 hasLocation W23171634981 @default.
• W2317163498 hasOpenAccess W2317163498 @default.
• W2317163498 hasPrimaryLocation W23171634981 @default.
• W2317163498 hasRelatedWork W1985839992 @default.
• W2317163498 hasRelatedWork W1995580211 @default.
• W2317163498 hasRelatedWork W1999949526 @default.
• W2317163498 hasRelatedWork W2039152901 @default.
• W2317163498 hasRelatedWork W2145594868 @default.
• W2317163498 hasRelatedWork W2157597826 @default.
• W2317163498 hasRelatedWork W2242287155 @default.
• W2317163498 hasRelatedWork W2341765369 @default.
• W2317163498 hasRelatedWork W2358596651 @default.
• W2317163498 hasRelatedWork W2373544838 @default.
• W2317163498 hasRelatedWork W2373982830 @default.
• W2317163498 hasRelatedWork W2376032488 @default.
• W2317163498 hasRelatedWork W2390376308 @default.
• W2317163498 hasRelatedWork W2402086363 @default.
• W2317163498 hasRelatedWork W2469515091 @default.
• W2317163498 hasRelatedWork W2533753256 @default.
• W2317163498 hasRelatedWork W2576909123 @default.
• W2317163498 hasRelatedWork W2598282385 @default.
• W2317163498 hasRelatedWork W2605240813 @default.
• W2317163498 hasRelatedWork W3029192993 @default.
• W2317163498 isParatext "false" @default.
• W2317163498 isRetracted "false" @default.
• W2317163498 magId "2317163498" @default.
• W2317163498 workType "article" @default.